Pre-demographic dividend vs Togo: Antiretroviral therapy coverage
Pre-demographic dividend
82.2%
in 2024
Togo
92.0%
in 2024
Pre-demographic dividend rank
11th
Togo rank
14th
Antiretroviral therapy coverage over time
- Pre-demographic dividend
- Togo
How they compare
Togo currently reports 92.0% against 82.2% in Pre-demographic dividend, a difference of 9.8%.
That makes Togo's figure about 1.1 times Pre-demographic dividend's.
The two have swapped places 5 times across 25 shared years of data; in 2000 it was Pre-demographic dividend ahead.
Pre-demographic dividend ranks 11th and Togo ranks 14th of 23 groups.
Across the 3 decades both report, Pre-demographic dividend averaged higher in 1 and Togo in 2.
Head to head by decade
| Decade | Pre-demographic dividend | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.1% | 4.6% | 0.5% | Pre-demographic dividend |
| 2010s | 41.8% | 44.8% | 3.0% | Togo |
| 2020s | 74.6% | 84.0% | 9.4% | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Pre-demographic dividend or Togo?
- Togo, at 92.0% against 82.2% in Pre-demographic dividend as of 2024.
- What is the difference in antiretroviral therapy coverage between Pre-demographic dividend and Togo?
- 9.8%, with Togo ahead.
- How many years of comparable data are there for Pre-demographic dividend and Togo?
- 25 years are reported by both, from 2000 to 2024.
- How do Pre-demographic dividend and Togo rank globally for antiretroviral therapy coverage?
- Pre-demographic dividend ranks 11th and Togo ranks 14th of 23 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.